Avacta Group PLC
LSE:AVCT

Watchlist Manager
Avacta Group PLC Logo
Avacta Group PLC
LSE:AVCT
Watchlist
Price: 77 GBX 1.32% Market Closed
Market Cap: 336.1m GBX

Avacta Group PLC
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Avacta Group PLC
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Avacta Group PLC
LSE:AVCT
Gross Profit
-ÂŁ4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Gross Profit
ÂŁ307.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Gross Profit
ÂŁ217.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Oxford BioMedica PLC
LSE:OXB
Gross Profit
ÂŁ66.7m
CAGR 3-Years
-4%
CAGR 5-Years
16%
CAGR 10-Years
23%
No Stocks Found

Avacta Group PLC
Glance View

Market Cap
336.1m GBX
Industry
Biotechnology

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. The firm is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. The company has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.

AVCT Intrinsic Value
55.94 GBX
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Avacta Group PLC's Gross Profit?
Gross Profit
-4.9m GBP

Based on the financial report for Jun 30, 2025, Avacta Group PLC's Gross Profit amounts to -4.9m GBP.

Back to Top